The presence of CD163-positive macrophages has been reported as a prognostic marker across various sarcoma subtypes, including leiomyosarcoma, myxoid liposarcoma, undifferentiated pleomorphic sarcoma, embryonal rhabdomyosarcoma, and synovial sarcoma [25,26]. This evidence concerns the gene CD163 and sarcoma.